KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

被引：0

作者：

F Loupakis

A Ruzzo

C Cremolini

B Vincenzi

L Salvatore

D Santini

G Masi

I Stasi

E Canestrari

E Rulli

I Floriani

K Bencardino

N Galluccio

V Catalano

G Tonini

M Magnani

G Fontanini

F Basolo

A Falcone

F Graziano

机构：

[1] Unit of Medical Oncology 2,Istituto Toscano Tumori and Department of Oncology

[2] Azienda-Ospedaliero Universitaria Pisana,Department of Biomolecular Sciences

[3] Transplantes and New Technologies in Medicine,Division of Pathology, Department of Surgery

[4] University of Pisa,undefined

[5] Section of Biochemistry and Molecular Biology “G. Fornaini”,undefined

[6] University of Urbino,undefined

[7] Unit of Medical Oncology,undefined

[8] University Campus Biomedico,undefined

[9] Via Alvaro del Portillo 200 – 00128 Rome,undefined

[10] Italy,undefined

[11] Mario Negri Institute for Pharmacological Research,undefined

[12] Via La Masa 19 – 20156 Milan,undefined

[13] Italy,undefined

[14] Unit of Medical Oncology,undefined

[15] San Raffaele Scientific Institute,undefined

[16] Via Olgettina 60 – 20132 Milan,undefined

[17] Italy,undefined

[18] Unit of Medical Oncology,undefined

[19] Hospital of Pesaro,undefined

[20] Via Lombroso 1 – 61100 Pesaro,undefined

[21] Italy,undefined

[22] University of Pisa,undefined

[23] Istituto Toscano Tumori,undefined

[24] Via Roma 67 – Pisa,undefined

[25] Italy,undefined

来源：

British Journal of Cancer | 2009年 / 101卷

关键词：

colorectal cancer; cetuximab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：715 / 721

页数：6

共 50 条

[41] Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
Weber, Juliane
McCormack, Paul L.
BIODRUGS, 2008, 22 (06) : 403 - 411
[42] Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Joris van de Haar
Xuhui Ma
Salo N. Ooft
Pim W. van der Helm
Louisa R. Hoes
Sara Mainardi
David J. Pinato
Kristi Sun
Lisa Salvatore
Giampaolo Tortora
Ina Valeria Zurlo
Silvana Leo
Riccardo Giampieri
Rossana Berardi
Fabio Gelsomino
Valeria Merz
Federica Mazzuca
Lorenzo Antonuzzo
Gerardo Rosati
Chara Stavraka
Paul Ross
Maria Grazia Rodriquenz
Michele Pavarana
Carlo Messina
Timothy Iveson
Federica Zoratto
Anne Thomas
Elisabetta Fenocchio
Margherita Ratti
Ilaria Depetris
Massimiliano Cergnul
Cristina Morelli
Michela Libertini
Alessandro Parisi
Michele De Tursi
Nicoletta Zanaletti
Ornella Garrone
Janet Graham
Raffaella Longarini
Stefania Maria Gobba
Angelica Petrillo
Emiliano Tamburini
Nicla La Verde
Fausto Petrelli
Vincenzo Ricci
Lodewyk F. A. Wessels
Michele Ghidini
Alessio Cortellini
Emile E. Voest
Nicola Valeri
Nature Medicine, 2023, 29 : 605 - 614
[43] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
Caglayan Geredeli
Nurgul Yasar
World Journal of Surgical Oncology, 16
[44] Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
van de Haar, Joris
Ma, Xuhui
Ooft, Salo N.
van der Helm, Pim W.
Hoes, Louisa R.
Mainardi, Sara
Pinato, David J.
Sun, Kristi
Salvatore, Lisa
Tortora, Giampaolo
Zurlo, Ina Valeria
Leo, Silvana
Giampieri, Riccardo
Berardi, Rossana
Gelsomino, Fabio
Merz, Valeria
Mazzuca, Federica
Antonuzzo, Lorenzo
Rosati, Gerardo
Stavraka, Chara
Ross, Paul
Rodriquenz, Maria Grazia
Pavarana, Michele
Messina, Carlo
Iveson, Timothy
Zoratto, Federica
Thomas, Anne
Fenocchio, Elisabetta
Ratti, Margherita
Depetris, Ilaria
Cergnul, Massimiliano
Morelli, Cristina
Libertini, Michela
Parisi, Alessandro
De Tursi, Michele
Zanaletti, Nicoletta
Garrone, Ornella
Graham, Janet
Longarini, Raffaella
Gobba, Stefania Maria
Petrillo, Angelica
Tamburini, Emiliano
La Verde, Nicla
Petrelli, Fausto
Ricci, Vincenzo
Wessels, Lodewyk F. A.
Ghidini, Michele
Cortellini, Alessio
Voest, Emile E.
Valeri, Nicola
NATURE MEDICINE, 2023, 29 (03) : 605 - +
[45] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
Geredeli, Caglayan
Yasar, Nurgul
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
[46] Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer
Teerapakpinyo, Chinachote
Wanthong, Phanni
Aumchaaumchaya, Mathawee
Chankate, Piyamai
Kaikeaw, Warisa
Tosakorn, Warunya
Shaungshoti, Shanop
ASIAN BIOMEDICINE, 2015, 9 (01) : 61 - 67
[47] BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Jing Chen
Fang Guo
Xin Shi
Lihua Zhang
Aifeng Zhang
Hui Jin
Youji He
BMC Cancer, 14
[48] BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Chen, Jing
Guo, Fang
Shi, Xin
Zhang, Lihua
Zhang, Aifeng
Jin, Hui
He, Youji
BMC CANCER, 2014, 14
[49] BEVACIZUMAB AFTER CETUXIMAB FAILURE IN KRAS WILD-TYPE METASTATIC COLORECTAL CARCINOMA
Lam, K. O.
Lee, Victor
Choi, Cheukwai
Liu, Rico
Leung, T. W.
Kwong, D. L. W.
ANNALS OF ONCOLOGY, 2012, 23 : 100 - 101
[50] Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J. C. von Einem
V. Heinemann
L. Fischer von Weikersthal
U. Vehling-Kaiser
M. Stauch
H. G. Hass
T. Decker
S. Klein
S. Held
A. Jung
T. Kirchner
M. Haas
J. Holch
M. Michl
P. Aubele
S. Boeck
C. Schulz
C. Giessen
S. Stintzing
D. P. Modest
Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1607 - 1614

← 1 2 3 4 5 →